key: cord-0884648-rvdiqcym
authors: Maier, Cheryl L; Truong, Alexander D; Auld, Sara C; Polly, Derek M; Tanksley, Christin-Lauren; Duncan, Alexander
title: COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?
date: 2020-05-25
journal: Lancet
DOI: 10.1016/s0140-6736(20)31209-5
sha: e6497a8d24cfdecd151e63e9370fa81d2ade56b4
doc_id: 884648
cord_uid: rvdiqcym

nan

Reports of thrombotic complica tions in patients with COVID19 are increasingly prominent, and these reports include patients receiving therapeutic anticoagulation. 1,2 At our institution, multiple occurrences of anticoagulation failure prompted us to search for alternative aetiologies contributing to refractory hypercoagu lability. Here we describe COVID19 associated hyperviscosity, a potentially severe consequence of infection with severe acute respiratory syn drome coronavirus 2, in 15 patients tested to date. This work was done ethically in accordance with institutional review board approval. All patients were critically ill with COVID19 pneumonia and admitted to the medical intensive care unit. 14 patients had acute respiratory distress syndrome requiring intuba tion, 14 patients were encephalopathic, 12 patients had shock requiring vasopressors, and 11 patients had renal failure requiring continuous renal replacement therapy (CRRT). All patients received anticoagulation according to an institutional protocol based on data suggesting increased venous thromboembolism rates when Ddimer concentrations exceed 3 μg/mL. 2 Five patients with Ddimer concentrations of 3 μg/mL or higher and known (or highly suspected) thrombosis received therapeutic anti coagulation. Two of the patients received intra venous heparin, and three patients received a direct thrombin inhibitor (argatroban or bivalirudin) because of heparin resistance or concern for heparininduced thrombocyto penia. Four patients with Ddimer concentrations below 3 μg/mL received lowdose thromboprophylaxis with low molecularweight heparin (LMWH) or subcutaneous heparin. Six patients with Ddimer concentrations of 3 μg/mL or more and without known throm bosis received intermediate dosing (ie, subtherapeutic) of LMWH or intravenous heparin.

The 15 patients had plasma viscosity exceeding 95% of normal, as determined by traditional cap illary viscometry, ranging from 1•9-4•2 centipoise (cP; normal range 1•4-1•8). Notably, the four patients with plasma viscosity above 3•5 cP had a documented thrombotic complication: one patient had pulmonary embolism, one patient had limb ischaemia and suspected pulmonary embolism, and two patients had CRRTrelated clotting. Plasma viscosity and Sequential Organ Failure Assessment scores, a measure of illness severity, were strongly correlated (Pearson's r=0•841, R²=0•7072, p<0•001; appendix).

Hyperviscosity damages endo thelium and is a known risk factor for thrombosis. 3 It can result from increases in cellular components or plasma proteins, such as fibrinogen or immunoglobulin, as seen in Waldenström macroglobulinaemia. Consistent with reports of hyper fibrinogenaemia in patients with COVID19, our patients had substantial ly increased fibrinogen concentra tions (median 708 mg/dL, range 459-1188; normal reference range 200-393). 4 Further study is needed to evaluate which plasma components, including acute phase proteins such as fibrinogen, contribute to COVID19associated hyperviscosity.

Our novel observation might provide an important link between inflammation and coagulopathy in critically ill patients with COVID19. We are actively exploring any beneficial role of therapeutic plasma exchange, a highly effective treatment for symptom atic hyperviscosity in other conditions such as hyper gammaglobulinaemia, in the clinical management of these patients. 5 Finally, any causal relationship between hyperviscosity and throm botic complications in COVID19 warrants immediate investigation given the potential to impact clinical care.

We declare no competing interests.

Autopsy findings and venous thromboembolism in patients with COVID19

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

The procoagulant pattern of patients with COVID19 acute respiratory distress syndrome

Guidelines on the use of therapeutic apheresis in clinical practice -evidencebased approach from the Writing Committee of the American Society for Apheresis: the eighth special issue

See Online for appendix